Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms
#1827
Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.
Aim(s): To find out whether resection of primary tumors prior to PRRT will result in better overall survival than without.
Materials and methods: Retrospectivly, we analyzed the data of 1048 patients with advanced NEN treated with PRRT. In 541/1045 patients (52%, group 1) primary tumors were removed. Group 2 enfolded 444 patients (42%) with no resection previously, no data: 60 patients (6%). Progression free survival (PFS) was determined by 68Ga SSTR-PET/CT and EORTC response criteria.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Kaemmerer D
Authors: Kaemmerer D, Twrznik M, Hommann M, Hörsch D, Baum R,
To read the full abstract, please log into your ENETS Member account.